MX2014012848A - Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino. - Google Patents

Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino.

Info

Publication number
MX2014012848A
MX2014012848A MX2014012848A MX2014012848A MX2014012848A MX 2014012848 A MX2014012848 A MX 2014012848A MX 2014012848 A MX2014012848 A MX 2014012848A MX 2014012848 A MX2014012848 A MX 2014012848A MX 2014012848 A MX2014012848 A MX 2014012848A
Authority
MX
Mexico
Prior art keywords
methylene
spirox
methyl
systems
menorrhagia
Prior art date
Application number
MX2014012848A
Other languages
English (en)
Inventor
Norbert Schmees
Harri Jukarainen
Reinhard Nubbemeyer
Lars Röse
Tuula Valo
Katja Prelle
Henriikka Korolainen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014012848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2014012848A publication Critical patent/MX2014012848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso intrauterino de 18-metil-15ß, 16ß-metilen-19-nor-20-espirox-4- en-3-onas de fórmula general (1) (ver Fórmula) en donde R6 y R7 son hidrógeno o un grupo metileno, para el tratamiento de la menorragia, de hemorragias intrauterinas en general, y un sistema intrauterino para dicho uso, que comprende un compuesto de fórmula 1.
MX2014012848A 2012-04-23 2013-04-19 Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino. MX2014012848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012206653 2012-04-23
PCT/EP2013/058152 WO2013160200A1 (de) 2012-04-23 2013-04-19 ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN

Publications (1)

Publication Number Publication Date
MX2014012848A true MX2014012848A (es) 2015-02-05

Family

ID=48141995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012848A MX2014012848A (es) 2012-04-23 2013-04-19 Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino.

Country Status (28)

Country Link
US (1) US20150119372A1 (es)
EP (1) EP2841073A1 (es)
JP (1) JP2015514789A (es)
KR (1) KR20150005548A (es)
CN (1) CN104379149A (es)
AR (1) AR090800A1 (es)
AU (1) AU2013251842A1 (es)
BR (1) BR112014026086A2 (es)
CA (1) CA2871001A1 (es)
CL (1) CL2014002857A1 (es)
CO (1) CO7111253A2 (es)
CR (1) CR20140489A (es)
CU (1) CU20140120A7 (es)
DO (1) DOP2014000240A (es)
EA (1) EA201491917A1 (es)
EC (1) ECSP14024263A (es)
GT (1) GT201400225A (es)
HK (1) HK1206271A1 (es)
IL (1) IL235096A0 (es)
MA (1) MA37443A1 (es)
MX (1) MX2014012848A (es)
PE (1) PE20142437A1 (es)
PH (1) PH12014502371A1 (es)
SG (1) SG11201406583QA (es)
TN (1) TN2014000445A1 (es)
TW (1) TW201345530A (es)
UY (1) UY34759A (es)
WO (1) WO2013160200A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
SG11201406583QA (en) 2014-11-27
EP2841073A1 (de) 2015-03-04
UY34759A (es) 2013-11-29
TN2014000445A1 (en) 2016-03-30
IL235096A0 (en) 2014-12-31
CR20140489A (es) 2014-12-24
PE20142437A1 (es) 2015-01-31
AR090800A1 (es) 2014-12-10
CA2871001A1 (en) 2013-10-31
ECSP14024263A (es) 2015-12-31
KR20150005548A (ko) 2015-01-14
BR112014026086A2 (pt) 2017-07-18
DOP2014000240A (es) 2015-02-15
CU20140120A7 (es) 2015-02-26
TW201345530A (zh) 2013-11-16
PH12014502371A1 (en) 2015-01-12
MA37443A1 (fr) 2016-05-31
JP2015514789A (ja) 2015-05-21
US20150119372A1 (en) 2015-04-30
GT201400225A (es) 2016-01-22
HK1206271A1 (en) 2016-01-08
CN104379149A (zh) 2015-02-25
CO7111253A2 (es) 2014-11-10
AU2013251842A1 (en) 2014-11-06
WO2013160200A1 (de) 2013-10-31
CL2014002857A1 (es) 2015-02-06
EA201491917A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
IN2015DN01156A (es)
MX2020006431A (es) Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2015015564A (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
MX2018005829A (es) Composiciones para tratar el cabello.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
PH12018500047A1 (en) Notch pathway signaling inhibitor compounds
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12015501038A1 (en) Inhibitors of iap
MX2015000980A (es) Inhibidores de aril lactama cinasa.
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP2576536A4 (en) INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE
MX363604B (es) Composición que comprende una combinación de un polímero acrílico y un copolímero de silicona y un aminoácido o un derivado de aminoácido.
PH12014501573A1 (en) Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
MX2014012848A (es) Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino.
TN2014000444A1 (en) INTRAUTERINE APPLICATION OF 18-METHYL-15β,16β-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE SYSTEMS, INTRAUTERINE SYSTEMS CONTAINING 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE, AS WELL AS THE USE THEREOF IN CONTRACEPTION AND GYNAECOLOGICAL THERAPY
WO2019055748A8 (en) Hydrogen-containing composition
GEP20197007B (en) Therapeutic agent for frontal lobe dysfunction
IN2013MU02732A (es)